Coherus BioSciences, Inc. financial data

Symbol
CHRS on Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
Location
C/O Dennis M. Lanfear, 333 Twin Dolphin Dr, Suite 600, Redwood City, CA
State of incorporation
DE
Fiscal year end
December 31
Former names
BioGenerics, Inc. (to 1/3/2012)
Latest financial report
10-K - Q4 2024 - Mar 17, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 120 % -36%
Quick Ratio 15.3 % -45.5%
Debt-to-equity -720 % -80.6%
Return On Assets 4.77 %

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 116M shares +1.02%
Common Stock, Shares, Outstanding 116M shares +3.03%
Entity Public Float 171M USD -47.4%
Common Stock, Value, Issued 12K USD +9.09%
Weighted Average Number of Shares Outstanding, Basic 115M shares +21.7%
Weighted Average Number of Shares Outstanding, Diluted 115M shares +21.9%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 93.3M USD -14.7%
Costs and Expenses 379M USD -17.8%
Operating Income (Loss) -112M USD +45%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest 28.5M USD +36.4%
Income Tax Expense (Benefit) -380K USD
Net Income (Loss) Attributable to Parent 28.5M USD +36.4%
Earnings Per Share, Basic 0.25 USD/shares +31.3%
Earnings Per Share, Diluted 0.25 USD/shares +43.3%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 126M USD +22.4%
Marketable Securities, Current 14.9M USD -88.4%
Inventory, Net 70.1M USD +12%
Assets, Current 342M USD -28.2%
Property, Plant and Equipment, Net 2.84M USD -44.6%
Operating Lease, Right-of-Use Asset 4.52M USD -23.6%
Intangible Assets, Net (Excluding Goodwill) 71.7M USD +1108%
Goodwill 943K USD 0%
Other Assets, Noncurrent 6.69M USD -30.9%
Assets 449M USD -28.8%
Accounts Payable, Current 28.5M USD -19.2%
Employee-related Liabilities, Current 18.3M USD -14.8%
Accrued Liabilities, Current 60.3M USD -42.8%
Liabilities, Current 283M USD -14.7%
Deferred Income Tax Liabilities, Net 1.1M USD 0%
Operating Lease, Liability, Noncurrent 3.29M USD -34%
Other Liabilities, Noncurrent 29.3M USD +133%
Liabilities 581M USD -29.5%
Accumulated Other Comprehensive Income (Loss), Net of Tax -275K USD -10.9%
Retained Earnings (Accumulated Deficit) -1.55B USD +1.81%
Stockholders' Equity Attributable to Parent -132M USD +31.8%
Liabilities and Equity 449M USD -28.8%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -46.8M USD +32%
Net Cash Provided by (Used in) Financing Activities 887K USD -76.7%
Net Cash Provided by (Used in) Investing Activities 203M USD +1057%
Common Stock, Shares Authorized 300M shares 0%
Common Stock, Shares, Issued 116M shares +3.03%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 157M USD
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 126M USD +22.2%
Deferred Tax Assets, Valuation Allowance 413M USD -2.49%
Deferred Tax Assets, Gross 419M USD -2.57%
Operating Lease, Liability 4.98M USD -22.2%
Payments to Acquire Property, Plant, and Equipment 152K USD -75.3%
Lessee, Operating Lease, Liability, to be Paid 5.85M USD -26.4%
Operating Lease, Liability, Current 1.69M USD +18.8%
Lessee, Operating Lease, Liability, to be Paid, Year Two 2.13M USD -3.01%
Lessee, Operating Lease, Liability, to be Paid, Year One 2.19M USD +4.63%
Operating Lease, Weighted Average Discount Rate, Percent 0.12 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 871K USD -43.6%
Lessee, Operating Lease, Liability, to be Paid, Year Three 1.53M USD -28%
Deferred Tax Assets, Operating Loss Carryforwards 158M USD -7.23%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 5M shares 0%
Unrecognized Tax Benefits 19.2M USD +10.5%
Lessee, Operating Lease, Liability, to be Paid, Year Four 1.53M USD +424%
Additional Paid in Capital 1.42B USD +2.38%
Preferred Stock, Shares Outstanding 0 shares
Amortization of Intangible Assets 1.2M USD
Depreciation, Depletion and Amortization 1.8M USD -43.8%
Deferred Tax Assets, Net of Valuation Allowance 6.32M USD -7.65%
Share-based Payment Arrangement, Expense 27.8M USD -35.5%
Interest Expense 27.2M USD -33%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%